[Skip to Navigation]
Sign In
Views 824
Citations 0
Editorial
September 2, 2021

Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench

Author Affiliations
  • 1Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston
  • 2Harvard Medical School, Boston, Massachusetts
JAMA Oncol. 2021;7(11):1615-1616. doi:10.1001/jamaoncol.2021.3369

Since the groundbreaking approval of crizotinib for the treatment of advanced ALK-rearranged (ALK-positive) non–small cell lung cancer (NSCLC) in 2011,1 the therapeutic landscape for this disease has evolved at a staggering pace. Indeed, the past decade has witnessed US Food and Drug Administration approvals of 4 additional ALK tyrosine kinase inhibitors (TKIs): ceritinib, alectinib, brigatinib, and lorlatinib.2-5 These next-generation ALK TKIs represent a significant advance compared with the first-generation ALK TKI crizotinib in terms of central nervous system penetration and overall potency.6,7 Although these promising characteristics initially positioned next-generation ALK TKIs as salvage therapies for crizotinib-resistant tumors, these drugs have since leapfrogged crizotinib and emerged as the preferred first-line option based on findings from multiple phase 3 studies.2-5 The tremendous successes of drug development for ALK-positive NSCLC and the rapid translation of these advances into significant survival gains have definitively established management of ALK-positive NSCLC as a model of precision medicine while also raising questions regarding ways to maximize benefit from the expanding repertoire of viable therapies.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×